Quanterix Corporation
MARKET-BEATING SCORE = 6/10
-----------------------------"engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics"
-----------------------------------
QTRX EPS growth 4,231.58% — above-market growth rate, typically outperforms the broad index.
QTRX revenue growing 18.20% YoY — strong top-line supports market-beating returns.
QTRX gross margin 46.80% — decent margin, competitive business model.
QTRX FCF $462.00M positive — real cash generation, the #1 long-run predictor of market outperformance.
QTRX D/E ratio 0.10 — conservative leverage, balance sheet resilience favors outperformance.
MARKET-BEATING SCORE = 6/10
-----------------------------"engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics"
-----------------------------------
QTRX EPS growth 4,231.58% — above-market growth rate, typically outperforms the broad index.
QTRX revenue growing 18.20% YoY — strong top-line supports market-beating returns.
QTRX gross margin 46.80% — decent margin, competitive business model.
QTRX FCF $462.00M positive — real cash generation, the #1 long-run predictor of market outperformance.
QTRX D/E ratio 0.10 — conservative leverage, balance sheet resilience favors outperformance.
交易進行
getting above the monthly support level is a good sign for investors in longpants. 
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。